Senate Finance Drug Pricing Bill May Gain Traction As Panel’s Lead Health Staffer Joins CMS
Arielle Woronoff joins the Biden Administration after four years of steering health policy at the Senate Finance Committee, including work on the Grassley-Wyden bill.
You may also be interested in...
Speculation is growing that the Institute for Clinical and Economic Review or something like it could become the US version of the government-sponsored health tecnology assessment bodies in Europe.
House Democrats push to remove the current limit on Medicaid rebates in upcoming COVID-19 relief package would likely leave many drug companies unscathed, but some expect bigger ticket drug pricing items will soon be on the agenda.
Nearly $70bn in savings over 10 years is expected to result from mandatory price inflation rebates for drugs covered by Medicare Part D.